Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Mar-Apr;17(2):222-226.
doi: 10.1097/ADM.0000000000001055. Epub 2022 Aug 24.

Breastfeeding on Injectable Opioid Agonist Therapy: A Case Report

Charissa J Patricelli  1 , Isabelle J Gouin, Shanlea Gordon, Nicole Carter, Arianne Albert, Vanessa Paquette, Karly Stewart, Shawn George, Karen Urbanoski
Affiliations
Case Reports

Breastfeeding on Injectable Opioid Agonist Therapy: A Case Report

Charissa J Patricelli et al. J Addict Med. 2023 Mar-Apr.

Abstract

Background: Injectable opioid agonist therapy (iOAT) is the highest-intensity treatment currently available in Canada for individuals with severe opioid use disorder. However, there is limited data on iOAT administration in the perinatal period, with no research, practice guidelines, or known reports of breastfeeding on iOAT. This article presents the first known case of an individual breastfeeding on iOAT.

Case summary: We present a case of a pregnant 32-year-old woman from Canada with severe opioid use disorder, who stabilized with iOAT and chose to breastfeed her infant. She presented to hospital at 38 + 6 gestation in labor, unstable in her substance use disorder despite multiple interventions and was initiated on iOAT (intravenous hydromorphone) shortly after delivery. Before initiation of breastfeeding the infant was admitted to the neonatal intensive care unit for monitoring. On day 9 of life the infant received breastmilk for the first time, and was discharged from neonatal intensive care unit on day 12 of life with no clinical evidence of sedation or respiratory depression. The infant maintained mixed feeding and at 58 days of life was discharged in the mother and father's care, a healthy infant with stable vitals.

Discussion: This case suggests positive infant and maternal health and social outcomes for breastfeeding on iOAT. Further research on perinatal iOAT use and the pharmacokinetics of high-dose hydromorphone in breastmilk is required to inform clinical practice guidelines to safely support individuals and their infants who are impacted by substance use.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

References

    1. Sirluck-Schroeder IE Hunt GS Wakelin RJ, et al. Injectable opioid agonist therapy in British Columbia: An effective treatment with persistent barriers. Commentary UBCMJ 2021;12(2):37–38.
    1. British Columbia Centre on Substance Use and B.C. Ministry of Health. Guidance for Injectable Opioid Agonist Treatment for Opioid Use Disorder. Vancouver, BC, Canada: British Columbia Centre on Substance Use (BCCSU), 2021; Available at: https://www.bccsu.ca/wp-content/uploads/2021/07/BC_iOAT_Guideline.pdf. Accessed March 1, 2022.
    1. Griffiths S Campbell DM Caudarella A, et al. Use of injectable opioid agonist therapy in a in-patient setting for a pregnant patient with opioid use disorder: A case report. J Addict Med 2021;15(5):435–438. - PubMed
    1. Hartwig C Haasen C Reimer J, et al. Pregnancy and birth under maintenance treatment with diamorphine (heroin): A case report. Eur Addict Res 2008;14(2):113–114. - PubMed
    1. Groh A Urlichs F Hillemacher T, et al. Case report: Pregnancy and birth under heroin-assisted treatment (HAT). Heroin Addict Relat Clin Prob 2014;16(2).

Publication types